In addition, our study highlights TGFβ3 as a predictive marker to inform patient stratification for palbociclib treatment in breast cancer, underscoring the robustness of in vivo genome-wide CRISPR screening approaches to identify actionable biomarkers of drug response. The gene discussed is TGFB3; the disease is breast carcinoma.